Parents seeking optimal protection for their newborns against respiratory syncytial virus now have clearer guidance on which prevention strategy offers superior outcomes. This population-level analysis challenges assumptions about the relative effectiveness of maternal vaccination versus direct infant immunization approaches. The French National Health Data System comparison examined two distinct RSV prevention pathways: maternal vaccination with RSVpreF during pregnancy versus passive immunization of infants with nirsevimab, a long-acting monoclonal antibody. The study tracked RSV-related hospitalizations and associated outcomes across thousands of mother-infant pairs, providing real-world effectiveness data beyond controlled trial environments. Nirsevimab demonstrated notably stronger protective effects against severe RSV disease requiring hospitalization compared to maternal RSVpreF vaccination outcomes. This finding carries substantial implications for pediatric preventive care protocols, particularly as RSV represents a leading cause of infant hospitalization during winter months. The comparative effectiveness data arrives at a critical juncture as healthcare systems worldwide implement RSV prevention programs following recent regulatory approvals of both interventions. However, the observational study design limits causal interpretations, and factors like timing of interventions, maternal antibody transfer efficiency, and seasonal viral circulation patterns could influence comparative outcomes. The French healthcare system's comprehensive data capture provides robust population-level insights, yet generalizability to other healthcare contexts requires careful consideration. This evidence contributes to an evolving understanding of optimal RSV prevention strategies, though individual clinical decisions should account for maternal health status, delivery timing, and local epidemiological patterns. The research represents confirmatory evidence supporting targeted infant immunization approaches while highlighting the complexity of comparing indirect maternal vaccination benefits against direct infant protection protocols.